Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population
Michael Bogart,1 Richard H Stanford,1 François Laliberté,2 Guillaume Germain,2 Jennifer W Wu,2 Mei Sheng Duh3 1GlaxoSmithKline plc, Research Triangle Park, NC, USA; 2Groupe d’Analyse, Ltée, Montréal, QC, Canada; 3Analysis Group Inc., Boston, MA,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-02-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/medication-adherence-and-persistence-in-chronic-obstructive-pulmonary--peer-reviewed-article-COPD |
| _version_ | 1817990749737713664 |
|---|---|
| author | Bogart M Stanford RH Laliberté F Germain G Wu JW Duh MS |
| author_facet | Bogart M Stanford RH Laliberté F Germain G Wu JW Duh MS |
| author_sort | Bogart M |
| collection | DOAJ |
| description | Michael Bogart,1 Richard H Stanford,1 François Laliberté,2 Guillaume Germain,2 Jennifer W Wu,2 Mei Sheng Duh3 1GlaxoSmithKline plc, Research Triangle Park, NC, USA; 2Groupe d’Analyse, Ltée, Montréal, QC, Canada; 3Analysis Group Inc., Boston, MA, USA Introduction: This longitudinal, retrospective cohort study of patients with COPD describes baseline characteristics, adherence, and persistence following initiation of inhaled corticosteroids (ICS)/long-acting β2-agonists (LABA)/long-acting muscarinic antagonists (LAMA) from multiple inhaler triple therapy (MITT).Methods: Patients aged ≥40 years receiving MITT between January 2012 and September 2015 were identified from the IQVIA™ Real-world Data Adjudicated Claims–USA database. MITT was defined as subjects with ≥1 overlapping days’ supply of three COPD medications (ICS, LABA, and LAMA). Adherence (proportion of days covered, PDC) and discontinuation (defined as a gap of 1, 30, 60, or 90 days of supply in any of the three components of the triple therapy) were calculated for each patient over 12 months of follow-up. In addition, analyses were stratified by number of inhalers.Results: In total, 14,635 MITT users were identified (mean age, 62 years). Mean PDC for MITT at 12 months was 0.37%. Mean PDC for the ICS/LABA and LAMA component at 12 months was 49% (0.49±0.31; median, 0.47) and 54% (0.54±0.33; 0.56), respectively. The proportion of adherent patients (PDC ≥0.8) at 12 months was 14% for MITT. Allowing for a 30-day gap from last day of therapy, 86% of MITT users discontinued therapy during follow-up.Conclusion: Patients with COPD had low adherence to and persistence with MITT in a real-world setting. Mean PDC for each single inhaler component was higher than the mean PDC observed with MITT. Reducing the number of inhalers may improve overall adherence to intended triple therapy.
Keywords: chronic obstructive pulmonary disease, COPD, medication adherence, inhaled corticosteroids, ICS, long-acting β2-agonists, LABA, long-acting muscarinic antagonists, LAMA, multiple inhaler triple therapy |
| first_indexed | 2024-04-14T01:03:05Z |
| format | Article |
| id | doaj.art-1ba87381bc2c449f882856058c203518 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-04-14T01:03:05Z |
| publishDate | 2019-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-1ba87381bc2c449f882856058c2035182022-12-22T02:21:19ZengDove Medical PressInternational Journal of COPD1178-20052019-02-01Volume 1434335244174Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured populationBogart MStanford RHLaliberté FGermain GWu JWDuh MSMichael Bogart,1 Richard H Stanford,1 François Laliberté,2 Guillaume Germain,2 Jennifer W Wu,2 Mei Sheng Duh3 1GlaxoSmithKline plc, Research Triangle Park, NC, USA; 2Groupe d’Analyse, Ltée, Montréal, QC, Canada; 3Analysis Group Inc., Boston, MA, USA Introduction: This longitudinal, retrospective cohort study of patients with COPD describes baseline characteristics, adherence, and persistence following initiation of inhaled corticosteroids (ICS)/long-acting β2-agonists (LABA)/long-acting muscarinic antagonists (LAMA) from multiple inhaler triple therapy (MITT).Methods: Patients aged ≥40 years receiving MITT between January 2012 and September 2015 were identified from the IQVIA™ Real-world Data Adjudicated Claims–USA database. MITT was defined as subjects with ≥1 overlapping days’ supply of three COPD medications (ICS, LABA, and LAMA). Adherence (proportion of days covered, PDC) and discontinuation (defined as a gap of 1, 30, 60, or 90 days of supply in any of the three components of the triple therapy) were calculated for each patient over 12 months of follow-up. In addition, analyses were stratified by number of inhalers.Results: In total, 14,635 MITT users were identified (mean age, 62 years). Mean PDC for MITT at 12 months was 0.37%. Mean PDC for the ICS/LABA and LAMA component at 12 months was 49% (0.49±0.31; median, 0.47) and 54% (0.54±0.33; 0.56), respectively. The proportion of adherent patients (PDC ≥0.8) at 12 months was 14% for MITT. Allowing for a 30-day gap from last day of therapy, 86% of MITT users discontinued therapy during follow-up.Conclusion: Patients with COPD had low adherence to and persistence with MITT in a real-world setting. Mean PDC for each single inhaler component was higher than the mean PDC observed with MITT. Reducing the number of inhalers may improve overall adherence to intended triple therapy. Keywords: chronic obstructive pulmonary disease, COPD, medication adherence, inhaled corticosteroids, ICS, long-acting β2-agonists, LABA, long-acting muscarinic antagonists, LAMA, multiple inhaler triple therapyhttps://www.dovepress.com/medication-adherence-and-persistence-in-chronic-obstructive-pulmonary--peer-reviewed-article-COPDChronic obstructive pulmonary disease (COPD)medication adherenceinhaled corticosteroids (ICS)long-acting β2-agonists (LABA)long-acting muscarinic-antagonists (LAMA)multiple inhaler triple therapy |
| spellingShingle | Bogart M Stanford RH Laliberté F Germain G Wu JW Duh MS Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population International Journal of COPD Chronic obstructive pulmonary disease (COPD) medication adherence inhaled corticosteroids (ICS) long-acting β2-agonists (LABA) long-acting muscarinic-antagonists (LAMA) multiple inhaler triple therapy |
| title | Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population |
| title_full | Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population |
| title_fullStr | Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population |
| title_full_unstemmed | Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population |
| title_short | Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population |
| title_sort | medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a usa commercially insured population |
| topic | Chronic obstructive pulmonary disease (COPD) medication adherence inhaled corticosteroids (ICS) long-acting β2-agonists (LABA) long-acting muscarinic-antagonists (LAMA) multiple inhaler triple therapy |
| url | https://www.dovepress.com/medication-adherence-and-persistence-in-chronic-obstructive-pulmonary--peer-reviewed-article-COPD |
| work_keys_str_mv | AT bogartm medicationadherenceandpersistenceinchronicobstructivepulmonarydiseasepatientsreceivingtripletherapyinausacommerciallyinsuredpopulation AT stanfordrh medicationadherenceandpersistenceinchronicobstructivepulmonarydiseasepatientsreceivingtripletherapyinausacommerciallyinsuredpopulation AT lalibertef medicationadherenceandpersistenceinchronicobstructivepulmonarydiseasepatientsreceivingtripletherapyinausacommerciallyinsuredpopulation AT germaing medicationadherenceandpersistenceinchronicobstructivepulmonarydiseasepatientsreceivingtripletherapyinausacommerciallyinsuredpopulation AT wujw medicationadherenceandpersistenceinchronicobstructivepulmonarydiseasepatientsreceivingtripletherapyinausacommerciallyinsuredpopulation AT duhms medicationadherenceandpersistenceinchronicobstructivepulmonarydiseasepatientsreceivingtripletherapyinausacommerciallyinsuredpopulation |